A study led by Joaquin Mateo at Vall d’Hebron Institute of Oncology found that circulating extracellular vesicles in the blood stream of patients with metastatic prostate cancer contain DNA/RNA material that captures cancer genomics and transcriptomic evolution. This discovery could lead to the development of biomarkers for therapy response and drug resistance in individual patients. Prostate cancer, the fifth leading cause of cancer death in men, has seen advancements in treatment, but metastatic cases still face challenges with drug resistance. This novel liquid biopsy technique offers a promising way to monitor tumor evolution and make real-time clinical decisions for better treatment outcomes.
Source link
Novel liquid biopsy methodology enables monitoring of disease evolution in patients with metastatic prostate cancer
